Mabwell (Shanghai) Bioscience Co., Ltd. Stock

Equities

688062

CNE100005RD2

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
34.9 CNY -2.79% Intraday chart for Mabwell (Shanghai) Bioscience Co., Ltd. -1.33% +6.76%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 384M 53.21M Sales 2025 * 1.11B 153M Capitalization 13.95B 1.93B
Net income 2024 * -862M -119M Net income 2025 * -594M -82.21M EV / Sales 2024 * 36.3 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 12.6 x
P/E ratio 2024 *
-16.2 x
P/E ratio 2025 *
-23.5 x
Employees 1,491
Yield 2024 *
-
Yield 2025 *
-
Free-Float 47.33%
More Fundamentals * Assessed data
Dynamic Chart
Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment MT
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting CI
Mabwell Scraps Licensing Deal With Yangtze River Pharma MT
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology CI
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711 CI
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5% MT
Certain A-Shares of Mabwell Bioscience Co., Ltd. are subject to a Lock-Up Agreement Ending on 18-JAN-2024. CI
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA CI
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial CI
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug MT
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs CI
More news
1 day-2.79%
1 week-1.33%
Current month-1.33%
1 month+2.71%
3 months+31.60%
6 months+22.46%
Current year+6.76%
More quotes
1 week
34.40
Extreme 34.4
36.99
1 month
29.80
Extreme 29.8
36.99
Current year
20.40
Extreme 20.4
37.00
1 year
19.44
Extreme 19.44
37.00
3 years
12.96
Extreme 12.96
37.00
5 years
12.96
Extreme 12.96
37.00
10 years
12.96
Extreme 12.96
37.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 17-06-30
Director of Finance/CFO 43 23-06-26
Chief Tech/Sci/R&D Officer 52 20-05-31
Members of the board TitleAgeSince
Director/Board Member 70 20-10-10
Director/Board Member 55 19-03-31
Chief Executive Officer 52 17-06-30
More insiders
Date Price Change Volume
24-05-08 34.9 -2.79% 3,066,773
24-05-07 35.9 -1.64% 1,350,862
24-05-06 36.5 +3.19% 3,207,003
24-04-30 35.37 -0.67% 1,324,850

End-of-day quote Shanghai S.E., May 07, 2024

More quotes
Mabwell Shanghai Bioscience Co Ltd is a China-based company mainly engaged in the research and development, production and sales of therapeutic biological products. The Company's main businesses include the establishment of new varieties of drugs and the discovery of some early projects, the organization and development of preclinical research and pharmacological effects, and the development of drugs for preclinical research. The Company is also engaged in the organization, management and development of clinical trials of research species. The Company's research on drugs covers autoimmune, tumor, metabolism, ophthalmology, infection and other disease fields. The Company conducts business in domestic and foreign markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.9 CNY
Average target price
35.92 CNY
Spread / Average Target
+2.91%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688062 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW